Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

作者：Yang Zhang, Miao‐Zhen Qiu, Jufeng Wang, Yanqiao Zhang, Ao Shen, Xianglin Yuan, Tao� Zhang, Xiaoli Wei, Hongyun Zhao, De‐Shen Wang, Qi Zhao, Gao-Zhun Xiong, Yanping Ji, Xuejun Liang, Gang Xia, Rui‐Hua Xu · 发表于：Cell Reports Medicine · 年份：2022 · DOI：10.1016/j.xcrm.2022.100814 · 被引用次数：53 · 研究领域：Gastric Cancer Management and Outcomes、HER2/EGFR in Cancer Research、Monoclonal and Polyclonal Antibodies Research

ARX788 is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate with AS269 as cytotoxic payload. In this phase 1 multicenter dose-expansion clinical trial, patients with HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma failing to respond to prior trastuzumab-based standard treatment were enrolled. Between July 15 th , 2019, and March 14 th , 2022, 30 participants were enrolled. Twenty-eight (93.3%) patients experienced at least one drug-related adverse event (AE) and 13.3% experienced grade 3 ARX788-related AEs. The confirmed objective response rate is 37.9% (95% confidence interval [CI]: 20.7%–57.7%) and the disease control rate is 55.2% (95% CI: 35.7%–73.6%). With a median follow up of 10 months, the median progression-free survival and overall survival are 4.1 (95% CI: 1.4–6.4) and 10.7 months (95% CI: 4.8–not reached), respectively. The median duration of response is 8.4 (95% CI: 2.1–18.9) months. ARX788 is well tolerated and has promising anti-tumor activity in patients with HER2-positive advanced gastric adenocarcinoma (ChinaDrugTrials.org.cn: CTR20190639).